Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Medtronic
Merck
Johnson and Johnson
Mallinckrodt

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR DEXONE 0.5


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Dexone 0.5

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004228 ↗ Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma Completed National Cancer Institute (NCI) Phase 3 2000-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
NCT00004228 ↗ Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma Completed Children's Oncology Group Phase 3 2000-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
NCT00025259 ↗ Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed National Cancer Institute (NCI) Phase 3 2002-09-01 This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease.
NCT00025259 ↗ Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed Children's Oncology Group Phase 3 2002-09-01 This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dexone 0.5

Condition Name

Condition Name for Dexone 0.5
Intervention Trials
Recurrent Plasma Cell Myeloma 34
Refractory Plasma Cell Myeloma 29
Acute Lymphoblastic Leukemia 19
Plasma Cell Myeloma 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dexone 0.5
Intervention Trials
Multiple Myeloma 58
Neoplasms, Plasma Cell 57
Leukemia 43
Precursor Cell Lymphoblastic Leukemia-Lymphoma 40
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dexone 0.5

Trials by Country

Trials by Country for Dexone 0.5
Location Trials
Canada 140
Australia 64
New Zealand 28
Puerto Rico 15
Switzerland 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dexone 0.5
Location Trials
Texas 64
Minnesota 59
California 46
Florida 44
Michigan 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dexone 0.5

Clinical Trial Phase

Clinical Trial Phase for Dexone 0.5
Clinical Trial Phase Trials
Phase 4 2
Phase 3 26
Phase 2/Phase 3 4
[disabled in preview] 54
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dexone 0.5
Clinical Trial Phase Trials
Recruiting 45
Completed 31
Active, not recruiting 30
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dexone 0.5

Sponsor Name

Sponsor Name for Dexone 0.5
Sponsor Trials
National Cancer Institute (NCI) 123
M.D. Anderson Cancer Center 30
Mayo Clinic 23
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dexone 0.5
Sponsor Trials
NIH 124
Other 122
Industry 35
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
McKinsey
Boehringer Ingelheim
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.